BioAtla (BCAB) Retained Earnings (2020 - 2026)
BioAtla's (BCAB) quarterly Retained Earnings came in at -$551.5 million in Q2 2026, down 6.04% on a YoY basis from -$587.0 million in Q2 2025, and little changed quarter-over-quarter from -$552.0 million in Q1 2026.
Analysis
BioAtla (BCAB) Retained Earnings (2020 - 2026) Analysis & Trends
BioAtla (BCAB) has reported Retained Earnings for 7 consecutive years, with -$551.5 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Retained Earnings fell 6.04% year-over-year to -$551.5 million; the trailing twelve-month figure through Jun 2026 stood at -$551.5 million (down 6.04% YoY), and the FY2025 full-year result was -$545.6 million, down 209.06% from the prior year.
- Retained Earnings steadied at -$551.5 million in Q2 2026 per BCAB's latest filing, from -$552.0 million in the prior quarter.
- Across five years, Retained Earnings topped out at $501.9 million in Q1 2025 and bottomed at -$552.0 million in Q1 2026.
- Historically, Retained Earnings has averaged $188.1 million across 5 years, with a median of $474.9 million in 2022.
- The sharpest annual moves came in 2022 and 2026: Retained Earnings surged 31.12% in 2022, then tumbled 209.98% in 2026.
- Over 5 years, Retained Earnings stood at $473.1 million in 2022, then rose by 2.92% to $486.9 million in 2023, then grew by 2.75% to $500.3 million in 2024, then slumped by 209.06% to -$545.6 million in 2025, then fell by 1.08% to -$551.5 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$551.5 million, -$552.0 million, and -$545.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.69 Bn | 192.70 Bn | 7.24 Bn | -22.28 Bn |
| 2 | Gilead Sciences | 179.87 Bn | 176.70 Bn | 6.22 Bn | 9.53 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 15.69 Bn |
| 4 | Regeneron Pharmaceuticals | 81.70 Bn | 73.71 Bn | 3.93 Bn | 37.62 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 558.00 Mn |
| 6 | Moderna | 54.28 Bn | 49.14 Bn | 52.00 Mn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 33.02 Bn | 29.71 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Biogen | 31.93 Bn | 30.64 Bn | 1.96 Bn | 20.97 Bn |
| 9 | Roivant Sciences | 29.27 Bn | 29.27 Bn | 1.16 Mn | 5.13 Bn |
| 10 | BioAtla | 2.33 Mn | 2.33 Mn | - | -551.54 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -551.54 Mn |
| Mar 31, 2026 | -552.00 Mn |
| Dec 31, 2025 | -545.65 Mn |
| Sep 30, 2025 | -535.90 Mn |
| Jun 30, 2025 | -520.10 Mn |
| Mar 31, 2025 | 501.91 Mn |
| Dec 31, 2024 | 500.30 Mn |
| Sep 30, 2024 | 494.12 Mn |
| Jun 30, 2024 | 491.93 Mn |
| Mar 31, 2024 | 489.21 Mn |
| Dec 31, 2023 | 486.93 Mn |
| Sep 30, 2023 | 484.04 Mn |
| Jun 30, 2023 | 480.52 Mn |
| Mar 31, 2023 | 476.68 Mn |
| Dec 31, 2022 | 473.14 Mn |
| Sep 30, 2022 | 407.89 Mn |
| Jun 30, 2022 | 404.43 Mn |
| Mar 31, 2022 | 400.62 Mn |
| Dec 31, 2021 | 397.14 Mn |
| Sep 30, 2021 | 393.58 Mn |